

CYFARFOD BWRDD PRIFYSGOL IECHYD UNIVERSITY HEALTH BOARD MEETING

| DYDDIAD Y CYFARFOD: DATE OF MEETING: | 30 March 2023 |
|--|--|
| TEITL YR ADRODDIAD: TITLE OF REPORT: | Implementing the 'A Healthier Mid and West Wales' Strategy |
| CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR: | Lee Davies, Director of Strategy and Planning |
| SWYDDOG ADRODD: REPORTING OFFICER: | Eldeg Rosser, Head of Capital Planning Helen Morgan Howard, Head of Engagement and Transformation Programme Office |

Pwrpas yr Adroddiad (dewiswch fel yn addas) Purpose of the Report (select as appropriate)

Er Sicrwydd/For Assurance

ADRODDIAD SCAA SBAR REPORT Sefyllfa / Situation

The report provides an update to the information presented to the Board in January 2023.

Cefndir / Background

A meeting was held in October 2022 with Welsh Government (WG) to discuss the next steps regarding our Programme Business Case (PBC) for a Healthier Mid and West Wales.

Following the meeting with Welsh Government, the following four key areas of work have been progressed:

- Clinical Strategy Review to align with the governance of other major schemes across NHS Wales, WG is commissioning an independent review of our clinical strategy as this underpins the Programme Business Case.
- Strategic Outline Case to ensure a consistent approach for all major capital schemes across Wales, WG has requested that a Strategic Outline Case (SOC) be prepared. WG has agreed that a single Strategic Outline Case (SOC) will be acceptable to cover the new urgent and planned care hospital build, Glangwili Hospital and Withybush Hospital.
- Technical Work in support of Land Selection Process surveys and other planning and commercial activities.
- Land Consultation on 4 August 2022, the Hywel Dda Board agreed to undertake a public consultation to gather views from the public, staff and stakeholders on the three shortlisted sites for the new urgent and planned care hospital. A public consultation was launched on 23 February 2023 and runs until 19 May 2023.

Asesiad / Assessment

Clinical Strategy Review

The terms of reference for the clinical review have been agreed with WG, who are in the process of undertaking the procurement of the review team. It is anticipated that a contract will be awarded by early May 2023, which is a delay to the original timescale. An internal Steering Group has been established to support the preparation for the review. The group is chaired by the Medical Director/Deputy Chief Executive and has multi-disciplinary clinical representation. There is a risk that due to the procurement delay that the timeline for undertaking this review could impact upon completion of the Strategic Outline Case.

Producing the Strategic Outline Case (SOC)

Work has continued on the development of the SOC including:

- Introduction and Strategic Case
- Economic Case
- Management Case
- Financial Case and Commercial Case

Subject to the completion of the Clinical Strategy Review, the target is to complete the draft version of the SOC by the end of June 2023. The Health Board is currently anticipating that WG funding for the development costs associated with the case will be available in 2023/24.

Technical Work in support of Land Selection Process

Ongoing discussions are being held with the owners of the nominated sites and their agents. Landowners have been made aware of access requirements for topographical surveys which are likely to commence in parallel with the land consultation timeframe. This and other technical survey work and commercial negotiations will continue up to the selection of a preferred site.

Land consultation

Following the launch of the consultation on 23 of February 2023, a number of engagement events have taken place both in-person and online to engage with staff, the public and key stakeholders identified through stakeholder analysis.

In-person activities have been run as informal drop in sessions with staff able to respond to queries and signpost to consultation and technical materials. Online events have been run with presentations followed by questions and answers.

During the initial 6 weeks of the consultation the engagement activities have been planned to ensure equal coverage across staff bases and localities. At these events, participants have been invited to complete equality monitoring forms which, along with completed questionnaires, have allowed us to understand who we have engaged with to date.

The remaining 6 weeks of the consultation will include targeted engagement with demographic groups who may not have responded to the level we would expect, and this will be reviewed at the mid-point review and the end-point review to engage as effectively as possible throughout the consultation period. Engagement will be online and face-to-face, as appropriate.

The current workplan anticipates that an update to the Board will be available in the summer of 2023 on the:

- Clinical Strategy Review
- Strategic Outline Case (SOC)
- Land selection process technical work
- Land selection process outcome of Land Consultation

Argymhelliad / Recommendation

The Board is requested to:

- NOTE the update on the Clinical Strategy Review
- **NOTE** the progress made on the Strategic Outline Case (SOC)
- **NOTE** the progress made in the land selection process and consultation launch

| Amcanion: (rhaid cwblhau) Objectives: (must be completed) | | |
|--|--|--|
| Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score: | Risk 1196 - Insufficient investment in facilities/equipment/digital infrastructure (risk score 16) | |
| Safon(au) Gofal ac lechyd: Health and Care Standard(s): | 1.1 Health Promotion, Protection and Improvement | |
| Amcanion Strategol y BIP: UHB Strategic Objectives: | All Strategic Objectives are applicable | |
| Amcanion Cynllunio Planning Objectives | 5C_22 Business Cases for A Healthier Mid and West Wales 3M Communications 4T Continuous engagement implementation | |
| Amcanion Llesiant BIP: UHB Well-being Objectives: <u>Hyperlink to HDdUHB Well-being</u> <u>Objectives Annual Report 2018-2019</u> | 9. All HDdUHB Well-being Objectives apply | |

| Gwybodaeth Ychwanegol: Further Information: | |
|---|-------------------------------------|
| Ar sail tystiolaeth: Evidence Base: | Contained in the body of the report |
| Rhestr Termau: Glossary of Terms: | Contained in the body of the report |
| Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Cyfarfod Bwrdd lechyd Prifysgol: | Welsh Government |
| Parties / Committees consulted prior to University Health Board: | |

| Effaith: (rhaid cwblhau) Impact: (must be completed) | |
|---|---|
| Ariannol / Gwerth am Arian: Financial / Service: | The PBC sets out both the revenue and capital funding assumptions for the programme including a detailed Financial Case section in the PBC |
| Ansawdd / Gofal Claf: Quality / Patient Care: | Implicit within the PBC. This is an integral part of the PBC case for change |
| Gweithlu: Workforce: | Implicit within the PBC. This is an integral part of the PBC case for change and is the subject of Workforce Appendix in support of the PBC |
| Risg: Risk: | Risk 1196 Insufficient investment in facilities/equipment/digital infrastructure |
| Cyfreithiol: Legal: | Implicit within the PBC |
| Enw Da: Reputational: | Implicit within the PBC |
| Gyfrinachedd: Privacy: | Implicit within the PBC |
| Cydraddoldeb: Equality: | There is an Equality & Health Impact Assessment which will remain 'live' through the duration of the programme |